{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dai Q"],"funding":["Opening Project of Zhejiang Provincial Top Key Discipline of Pharmaceutical Sciences","National Key R&D Program of China","Natural Science Foundation of Zhejiang Province","Research Development Fund of Wenzhou Medical University","Medicine Health Science and Technology Plan of Zhejiang Province","National Natural Science Foundation of China","Key Science and Technology Development Plan from Wenzhou City"],"pagination":["3091-3102"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7957202"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(6)"],"pubmed_abstract":["Diabetic vascular complications are closely associated with long-term vascular dysfunction and poor neovascularization. Endothelial progenitor cells (EPCs) play pivotal roles in maintaining vascular homeostasis and triggering angiogenesis, and EPC dysfunction contributes to defective angiogenesis and resultant diabetic vascular complications. Fibroblast growth factor 21 (FGF21) has received substantial attention as a potential therapeutic agent for diabetes via regulating glucose and lipid metabolism. However, the effects of FGF21 on diabetic vascular complications remain unclear. In the present study, the in vivo results showed that FGF21 efficiently improved blood perfusion and ischaemic angiogenesis in both type 1 and type 2 diabetic mice, and these effects were accompanied by enhanced "],"journal":["Journal of cellular and molecular medicine"],"pubmed_title":["FGF21 promotes ischaemic angiogenesis and endothelial progenitor cells function under diabetic conditions in an AMPK/NAD+-dependent manner."],"pmcid":["PMC7957202"],"funding_grant_id":["51901160","2018KY769","2017KY106","81770305","Y20160082","81700732","LY16H020010","Q19E010021","81670767","QTJ15014","81873466","YKFJ002","2017YFA0506000"],"pubmed_authors":["Zhang G","Pan X","Yu L","Fan X","Ling X","He J","Chen H","Yan X","Meng X","Wang K","Dai X","Da S","Gu C","Dai Q","Sun S","Hu H","Tan Y","Chen X","Su Y","Zhang C"],"additional_accession":[]},"is_claimable":false,"name":"FGF21 promotes ischaemic angiogenesis and endothelial progenitor cells function under diabetic conditions in an AMPK/NAD+-dependent manner.","description":"Diabetic vascular complications are closely associated with long-term vascular dysfunction and poor neovascularization. Endothelial progenitor cells (EPCs) play pivotal roles in maintaining vascular homeostasis and triggering angiogenesis, and EPC dysfunction contributes to defective angiogenesis and resultant diabetic vascular complications. Fibroblast growth factor 21 (FGF21) has received substantial attention as a potential therapeutic agent for diabetes via regulating glucose and lipid metabolism. However, the effects of FGF21 on diabetic vascular complications remain unclear. In the present study, the in vivo results showed that FGF21 efficiently improved blood perfusion and ischaemic angiogenesis in both type 1 and type 2 diabetic mice, and these effects were accompanied by enhanced ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-20T02:27:30.411Z","creation":"2025-04-20T02:27:30.411Z"},"accession":"S-EPMC7957202","cross_references":{"pubmed":["33599110"],"doi":["10.1111/jcmm.16369"]}}